Amgen Inc., of Thousand Oaks, Calif., and the University of Texas MD Anderson Cancer Center formed a research collaboration focused on Amgen's bispecific T-cell engager antibody constructs, an immunotherapy that serves as a bridge between T cells and cancer cells.